Scarica l'app Stockscreener
167.74
9.23%
-17.06
Pre-mercato:
169.08
1.34
+0.80%
Precedente Chiudi:
$184.80
Aprire:
$178.65
Volume 24 ore:
1.24M
Relative Volume:
1.27
Capitalizzazione di mercato:
$8.28B
Reddito:
$4.02B
Utile/perdita netta:
$-142.16M
Rapporto P/E:
-56.74
EPS:
-2.9563
Flusso di cassa netto:
$518.49M
1 W Prestazione:
-5.20%
1M Prestazione:
+6.16%
6M Prestazione:
-12.16%
1 anno Prestazione:
+53.89%
Intervallo 1D:
$165.55
$180.85
Intervallo di 1 settimana:
$165.55
$190.14
Portata 52W:
$108.10
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
167.74 | 9.03B | 4.02B | -142.16M | 518.49M | -2.9563 |
TMO
Thermo Fisher Scientific Inc
|
466.70 | 194.94B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
178.57 | 137.69B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.93 | 45.19B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.42 | 34.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
311.20 | 32.91B | 3.17B | 642.63M | 516.49M | 10.77 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-11-17 | Aggiornamento | Argus | Hold → Buy |
| 2025-11-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-05-08 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-03 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Downgrade | UBS | Buy → Neutral |
| 2024-11-18 | Downgrade | CLSA | Hold → Underperform |
| 2024-11-07 | Aggiornamento | CLSA | Underperform → Hold |
| 2024-10-23 | Iniziato | CLSA | Underperform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Sell |
| 2024-10-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-01 | Downgrade | Citigroup | Neutral → Sell |
| 2024-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Downgrade | Argus | Buy → Hold |
| 2024-06-07 | Iniziato | Mizuho | Neutral |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-09-13 | Iniziato | TD Cowen | Market Perform |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Iniziato | Guggenheim | Neutral |
| 2022-04-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-07 | Iniziato | Stephens | Overweight |
| 2022-02-17 | Reiterato | BofA Securities | Buy |
| 2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-17 | Reiterato | Deutsche Bank | Buy |
| 2022-02-17 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-17 | Reiterato | UBS | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-04-21 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Iniziato | SVB Leerink | Outperform |
| 2019-04-30 | Ripresa | Evercore ISI | Outperform |
| 2018-12-14 | Iniziato | Deutsche Bank | Buy |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Charles River Laboratories International Inc (CRL) Shares Fall 9 - GuruFocus
Charles River Laboratories International Drops 7.2% Amid Sector-Wide Selling - AlphaStreet
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
What you need to know ahead of Charles River Laboratories' earnings release - MSN
Charles River gains new outperform at RBC despite NAMs related disruption - MSN
Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Rebound - simplywall.st
Assessing Charles River Laboratories (CRL) Valuation After Progress In Virtual Control Group Toxicology Studies - Yahoo Finance
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Highlights Effectiveness of VCGs in Toxicology - PharmiWeb.com
Charles River Laboratories Expected to Report Q1 2026 Earnings - HarianBasis.co
Is Cheaper Energy and Shipping Altering The Investment Case For Charles River Laboratories (CRL)? - simplywall.st
What You Need to Know Ahead of Charles River Laboratories' Earnings Release - Yahoo Finance
Charles River Labs stock (US1598641074): Why Google Discover changes matter more now - AD HOC NEWS
Charles River (CRL) Stock: Should You Invest (Gains) 2026-04-18Community Exit Signals - UBND thành phố Hải Phòng
Charles River Laboratories Experiences Evaluation Revision Amid Mixed Market Signals - Markets Mojo
Charles River Laboratories International, Inc. $CRL Shares Purchased by Assetmark Inc. - MarketBeat
A Look at Charles River Laboratories International Inc (CRL) Aft - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact? - TradingKey
Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call - BioSpace
Charles River Laboratories International, Inc. (NYSE:CRL) Sees Large Increase in Short Interest - MarketBeat
Why Charles River (CRL) Is Up 5.8% After Divesting Units And Refreshing Its Leadership Team - Yahoo Finance
Charles River Laboratories International (NYSE:CRL) Stock Rating Upgraded by Royal Bank Of Canada - MarketBeat
Charles River gains new Outperform at RBC despite NAMs related disruption - Seeking Alpha
Drug Development Services Market Research Report 2026: $50+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.
RBC Initiates Charles River Laboratories International at Outperform With $215 Price Target - marketscreener.com
3 Stocks with Moat Rating Changes This Month - Morningstar
RBC Capital initiates Charles River Labs stock at Outperform - Investing.com
RBC Capital initiates Charles River Labs stock at Outperform By Investing.com - Investing.com South Africa
Massachusetts Financial Services Co. MA Takes Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Does Charles River’s NSG BioLabs Tie-Up Reshape the Bull Case For Charles River Laboratories (CRL)? - Sahm
Charles River Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Q3 2025 Charles River Laboratories International Inc Earnings Call Transcript - GuruFocus
Charles River Laboratories International (CRL) Positioned to Benefit from Preclinical Research Activity and Biotech Funding Recovery - insidermonkey.com
Charles River, American Heart Association Partner to Advance Cardiovascular Health Awareness - Contract Pharma
Charles River Labs stock: Margin Boost from Divestitures Signals Buy Opportunity - AD HOC NEWS
Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Associa - PharmiWeb.com
Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association - The National Law Review
Charles River Labs stock: New Asia partnership signals growth potential - AD HOC NEWS
Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):